Recent developments highlight regulatory clearances, geographic expansion, strategic acquisitions, and product innovation.

• Nano-X received FDA 510(k) clearance for TAP2D, a cloud-enabled image enhancement for its Nanox.ARC systems in February 2026 [S2].
• The company expanded its Nanox.ARC distribution network in Serbia, Montenegro, and Bosnia and Herzegovina in January 2026 [N2].
• Nano-X announced the acquisition of VasoHealthcare IT to enhance its U.S. AI imaging expansion in November 2025 [N7].
• Nano-X introduced advanced 3D imaging technology at Keiser University to improve medical training and diagnostic accuracy in mid-2025 [N/A].
• Nano-X AI received the EU MDR CE Mark for HealthOST, enhancing bone health analysis and osteoporosis detection as of June 2025 [N/A].

The company has demonstrated progress in regulatory approvals, product innovation, and geographic expansion. Its acquisition of VasoHealthcare IT aims to accelerate AI imaging deployment in the U.S., while new distribution agreements in Europe broaden market access. The pay-per-scan model may provide scalable recurring revenue streams. Strong liquidity ratios support ongoing operations and investment in growth initiatives.

Nano-X reported a significant net loss of $75 million for fiscal 2025, indicating ongoing operational challenges. The company faces risks related to regulatory approvals, market acceptance of its technology, and competition in the medical imaging sector. Execution risks include integration of acquisitions and scaling the pay-per-scan model. Macroeconomic and geopolitical factors, including the situation in Israel, may also impact operations.

Nano-X's moat is based on its proprietary digital tomosynthesis technology combined with AI-enabled imaging enhancements and a pay-per-scan business model that differentiates it from traditional medical imaging providers. Regulatory clearances such as FDA 510(k) and EU MDR CE Mark support its product credibility. Strategic distribution partnerships and acquisitions further enhance its market reach and technological capabilities.

• Regulatory Risks: The company depends on obtaining and maintaining regulatory clearances such as FDA and EU approvals for its imaging systems and enhancements.
• Market Acceptance: Adoption of the Nanox.ARC system and the pay-per-scan business model by healthcare providers is critical to revenue growth.
• Financial Sustainability: Significant net losses and reliance on capital raises pose risks to long-term financial stability.
• Operational Execution: Risks related to integration of acquisitions, manufacturing scale-up, and global commercialization efforts.
• Geopolitical and Macroeconomic Risks: Operations may be affected by geopolitical tensions in Israel and global economic factors such as inflation and supply chain disruptions.

• Nano-X Imaging Ltd. is an Israel-based company focused on medical imaging technology.
• The company develops and commercializes the Nanox.ARC digital tomosynthesis system and related imaging technologies.
• Nano-X operates a pay-per-scan business model for its imaging systems.
• The company has received FDA 510(k) clearance for TAP2D, a cloud-enabled image enhancement capability for its Nanox.ARC and Nanox.ARC X systems as of February 2026 [S2].
• Nano-X expanded its distribution network in Europe, specifically in Serbia, Montenegro, and Bosnia and Herzegovina, through new Nanox.ARC distribution engagements as of January 2026 [N2].
• The company announced the acquisition of VasoHealthcare IT to enhance its U.S. AI imaging expansion efforts in November 2025 [N7].
• Nano-X introduced advanced 3D imaging technology at Keiser University to improve medical training and diagnostic accuracy as of July 2025 [N/A].
• Nano-X AI received the EU MDR CE Mark for HealthOST, a product enhancing bone health analysis and osteoporosis detection as of June 2025 [N/A].
• Financial figures as of December 31, 2025, include revenue of $13.0 million, net loss of $75.0 million, and basic and diluted EPS of -$1.16 per share [S1].
• Liquidity ratios as of December 31, 2025, show a current ratio of 3.96 and a cash ratio of 4, with cash and equivalents totaling approximately $49.2 million and short-term investments of $18.4 million [S1].
• The company completed a registered direct offering in November 2025, raising approximately $15 million in gross proceeds for working capital and general corporate purposes [S1].
• Nano-X operates under U.S. GAAP accounting standards and files annual reports on Form 20-F [S1].